Related Experiment Video

Updated: Jun 26, 2025

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.4K

Time for Clinical Dopamine Transporter Scans in Parkinsonism?: Not DAT Yet

Daniel G Di Luca1, Joel S Perlmutter1

  • 1From the Department of Neurology, Washington University in St. Louis, MO.

Neurology
|May 17, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.2K
Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking
14:21

Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking

Published on: August 6, 2013

18.3K

Related Experiment Videos

Last Updated: Jun 26, 2025

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.4K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.2K
Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking
14:21

Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking

Published on: August 6, 2013

18.3K

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

263
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
263
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

533
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
533

Articles linked to this work by shared authors, journal, and citation graph.

Interrater and Intrarater Reliability of the TWSTRS-Delphi Motor Severity Scale for Cervical Dystonia.

Movement disorders clinical practice·2026

Blood-based circular RNAs for early diagnosis of Alzheimer's disease.

Nature medicine·2026

A multimodal biomarker strategy to enhance diagnostic precision in neurodegenerative parkinsonism.

Nature medicine·2026

Low overlap of plasma and CSF protein quantitative trait loci affects protein discovery for neurological disease.

Science translational medicine·2026

Kinetic Modeling of a Novel Putative Sphingosine-1-Phosphate Receptor 1 (S1PR1) Radiotracer [18F]TZ82112 in Nonhuman Primates.

Journal of neurochemistry·2026

Racial and Ethnic Diversity in Clinical Trials for Disease Modifying Drugs in Parkinson Disease: A Systematic Review & Meta-Analysis.

Movement disorders clinical practice·2025

Carotid Artery Stenting Is Now an Evidence-Based Adjunct to Intensive Medical Therapy for Stroke Prevention.

Neurology·2026

Autonomic Network Signatures of Interictal Cardiorespiratory Dysfunction in Patients With Temporal Lobe Epilepsy.

Neurology·2026

Evaluation of Disease Severity Using CSF Biomarkers in Patients With Probable Cerebral Amyloid Angiopathy.

Neurology·2026

Repairing the Amyotrophic Lateral Sclerosis Trial Credibility Gap.

Neurology·2026

Association Between Immigration Status and the Intensity of Acute Stroke Care in Ontario, Canada: A Retrospective Study.

Neurology·2026

Gestational Changes in Antiseizure Medication Concentrations and the Impact of Polytherapy: A Prospective Multicenter Cohort Study in China.

Neurology·2026

Virtual screening of human pancreatic lipase inhibitors using an integrated transfer learning and molecular dynamics simulation.

Bioinformation·2026

The Evolution of Medications for Obesity Management.

JGH open : an open access journal of gastroenterology and hepatology·2026

Elucidating the release and permeation mechanisms of emulsion-type cataplasms from a structural perspective.

International journal of pharmaceutics·2026

Dapagliflozin as an adjunct to insulin improves glycemic control, weight, and lipid profile with a superior safety profile in type 2 diabetes: a randomized trial.

Clinics (Sao Paulo, Brazil)·2026

Standardizing pre-existing anti-PEG antibody detection: A key to clarifying their binding features and clinical relevance.

Journal of pharmaceutical analysis·2026

Pharmacist-led medication therapy management improving medication adherence in a patient with type 2 diabetes: case report.

Frontiers in medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us